1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Next Generation Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Next Generation Cancer Diagnostics Market, by Technology
8.1.1. Next-generation Sequencing
8.1.1.1. Market Revenue and Forecast
8.1.2. Lab-on-a-chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
8.1.2.1. Market Revenue and Forecast
8.1.3. qPCR & Multiplexing
8.1.3.1. Market Revenue and Forecast
8.1.4. Protein Microarrays
8.1.4.1. Market Revenue and Forecast
8.1.5. DNA Microarrays
8.1.5.1. Market Revenue and Forecast
9.1. Next Generation Cancer Diagnostics Market, by Application
9.1.1. Biomarker Development
9.1.1.1. Market Revenue and Forecast
9.1.2. Proteomic Analysis
9.1.2.1. Market Revenue and Forecast
9.1.3. CTC Analysis
9.1.3.1. Market Revenue and Forecast
9.1.4. Epigenetic Analysis
9.1.4.1. Market Revenue and Forecast
9.1.5. Genetic Analysis
9.1.5.1. Market Revenue and Forecast
10.1. Next Generation Cancer Diagnostics Market, by Cancer Type
10.1.1. Lung Cancer
10.1.1.1. Market Revenue and Forecast
10.1.2. Colorectal Cancer
10.1.2.1. Market Revenue and Forecast
10.1.3. Breast Cancer
10.1.3.1. Market Revenue and Forecast
10.1.4. Cervical Cancer
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. Next Generation Cancer Diagnostics Market, by Function
11.1.1. Therapeutic Monitoring
11.1.1.1. Market Revenue and Forecast
11.1.2. Prognostics
11.1.2.1. Market Revenue and Forecast
11.1.3. Companion Diagnostics
11.1.3.1. Market Revenue and Forecast
11.1.4. Cancer Screening
11.1.4.1. Market Revenue and Forecast
11.1.5. Risk Analysis
11.1.5.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Technology
12.1.2. Market Revenue and Forecast, by Application
12.1.3. Market Revenue and Forecast, by Cancer Type
12.1.4. Market Revenue and Forecast, by Function
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Technology
12.1.5.2. Market Revenue and Forecast, by Application
12.1.5.3. Market Revenue and Forecast, by Cancer Type
12.1.5.4. Market Revenue and Forecast, by Function
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Technology
12.1.6.2. Market Revenue and Forecast, by Application
12.1.6.3. Market Revenue and Forecast, by Cancer Type
12.1.6.4. Market Revenue and Forecast, by Function
12.2. Europe
12.2.1. Market Revenue and Forecast, by Technology
12.2.2. Market Revenue and Forecast, by Application
12.2.3. Market Revenue and Forecast, by Cancer Type
12.2.4. Market Revenue and Forecast, by Function
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Technology
12.2.5.2. Market Revenue and Forecast, by Application
12.2.5.3. Market Revenue and Forecast, by Cancer Type
12.2.5.4. Market Revenue and Forecast, by Function
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Technology
12.2.6.2. Market Revenue and Forecast, by Application
12.2.6.3. Market Revenue and Forecast, by Cancer Type
12.2.6.4. Market Revenue and Forecast, by Function
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Technology
12.2.7.2. Market Revenue and Forecast, by Application
12.2.7.3. Market Revenue and Forecast, by Cancer Type
12.2.7.4. Market Revenue and Forecast, by Function
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Technology
12.2.8.2. Market Revenue and Forecast, by Application
12.2.8.3. Market Revenue and Forecast, by Cancer Type
12.2.8.4. Market Revenue and Forecast, by Function
12.3. APAC
12.3.1. Market Revenue and Forecast, by Technology
12.3.2. Market Revenue and Forecast, by Application
12.3.3. Market Revenue and Forecast, by Cancer Type
12.3.4. Market Revenue and Forecast, by Function
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Technology
12.3.5.2. Market Revenue and Forecast, by Application
12.3.5.3. Market Revenue and Forecast, by Cancer Type
12.3.5.4. Market Revenue and Forecast, by Function
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Technology
12.3.6.2. Market Revenue and Forecast, by Application
12.3.6.3. Market Revenue and Forecast, by Cancer Type
12.3.6.4. Market Revenue and Forecast, by Function
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Technology
12.3.7.2. Market Revenue and Forecast, by Application
12.3.7.3. Market Revenue and Forecast, by Cancer Type
12.3.7.4. Market Revenue and Forecast, by Function
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Technology
12.3.8.2. Market Revenue and Forecast, by Application
12.3.8.3. Market Revenue and Forecast, by Cancer Type
12.3.8.4. Market Revenue and Forecast, by Function
12.4. MEA
12.4.1. Market Revenue and Forecast, by Technology
12.4.2. Market Revenue and Forecast, by Application
12.4.3. Market Revenue and Forecast, by Cancer Type
12.4.4. Market Revenue and Forecast, by Function
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Technology
12.4.5.2. Market Revenue and Forecast, by Application
12.4.5.3. Market Revenue and Forecast, by Cancer Type
12.4.5.4. Market Revenue and Forecast, by Function
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Technology
12.4.6.2. Market Revenue and Forecast, by Application
12.4.6.3. Market Revenue and Forecast, by Cancer Type
12.4.6.4. Market Revenue and Forecast, by Function
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Technology
12.4.7.2. Market Revenue and Forecast, by Application
12.4.7.3. Market Revenue and Forecast, by Cancer Type
12.4.7.4. Market Revenue and Forecast, by Function
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Technology
12.4.8.2. Market Revenue and Forecast, by Application
12.4.8.3. Market Revenue and Forecast, by Cancer Type
12.4.8.4. Market Revenue and Forecast, by Function
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Technology
12.5.2. Market Revenue and Forecast, by Application
12.5.3. Market Revenue and Forecast, by Cancer Type
12.5.4. Market Revenue and Forecast, by Function
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Technology
12.5.5.2. Market Revenue and Forecast, by Application
12.5.5.3. Market Revenue and Forecast, by Cancer Type
12.5.5.4. Market Revenue and Forecast, by Function
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Technology
12.5.6.2. Market Revenue and Forecast, by Application
12.5.6.3. Market Revenue and Forecast, by Cancer Type
12.5.6.4. Market Revenue and Forecast, by Function
13.1. GE HealthCare
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Koninklijke Philips N.V.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Novartis AG
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffmann-La Roche Ltd
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Illumina, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. QIAGEN
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Agilent Technologies, Inc. (Dako)
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Abbott
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Thermo Fisher Scientific Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Janssen Pharmaceuticals, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
